

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Laurence CHRISTA *et al.*

Serial No.: 10/561,034

Filed: December 16, 2005

For: HIP/PAP POLYPEPTIDE COMPOSITION
FOR USE IN LIVER REGENERATION AND
FOR THE PREVENTION OF LIVER
FAILURE

Group Art Unit: 1646

Examiner: Howard, Zachary C.

Atty. Dkt. No.: CHEP:015US/10513205


Confirmation No.: 9442

CERTIFICATE OF ELECTRONIC TRANSMISSION
37 C.F.R. § 1.8

I hereby certify that this correspondence is being
electronically filed with the United States Patent and
Trademark Office via EFS-Web on the date below.

October 19, 2010

Date


Mark B. Wilson

**SUPPLEMENTAL RESPONSE TO OFFICE ACTION
DATED FEBRUARY 18, 2010**

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 23313-1450

Sir:

Applicants submit this Supplemental Response to the Office Action dated February 18, 2010, for which Applicants filed a response on August 17, 2010. This Supplemental Response is submitted for the purpose of providing the Declaration of Dr. Jamila Faivre¹ (“Declaration”), which provides additional support for certain arguments against the enablement rejections that

¹ Dr. Faivre is an employee of INSERM, the assignee of the claimed intellectual property. This information is being disclosed to comply with Applicants’ duty to disclose information under 37 C.F.R. § 1.56 to the U.S. Patent Office. *See, e.g., Ferring B.V. v. Barr Labs, Inc.*, 437 F.3d 1181 (Fed. Cir. 2006).

Applications made at pages 10–11 of the Response dated August 17, 2010. The Declaration of Dr. Faivre is submitted herewith as Appendix A.

No fees are believed due in connection with the filing of the instant paper. However, should any such fees become due under 37 C.F.R. §§ 1.16 to 1.21 for any reason relating to the instant response, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski L.L.P. Account No. 50-1212.

Remarks begin on page 3 of this paper.